Published in Blood on December 01, 1990
Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J Exp Med (1996) 2.41
Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science (2011) 2.15
The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS (2011) 1.94
Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic Syndr (2009) 1.69
The macrophage in HIV-1 infection: from activation to deactivation? Retrovirology (2010) 1.64
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev (1995) 1.63
The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol (2009) 1.55
Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS (2011) 1.42
Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages. Infect Immun (1992) 1.42
B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma. Cancer Epidemiol Biomarkers Prev (2011) 1.41
Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol (2012) 1.39
HIV-associated chronic immune activation. Immunol Rev (2013) 1.38
Acute coronary syndromes in human immunodeficiency virus patients: a meta-analysis investigating adverse event rates and the role of antiretroviral therapy. Eur Heart J (2011) 1.26
Human immunodeficiency virus-1 Tat activates NF-κB via physical interaction with IκB-α and p65. Nucleic Acids Res (2011) 1.16
Envelope glycoproteins of human immunodeficiency virus type 1: profound influences on immune functions. Microbiol Rev (1996) 1.13
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int (2009) 1.13
CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS One (2010) 1.09
Immune activation and viral burden in acute disease induced by simian immunodeficiency virus SIVsmmPBj14: correlation between in vitro and in vivo events. J Virol (1994) 1.05
Loss and dysregulation of Th17 cells during HIV infection. Clin Dev Immunol (2013) 1.04
The VP7 outer capsid protein of rotavirus induces polyclonal B-cell activation. J Virol (2004) 1.01
Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD4+ T cells. J Virol (2007) 1.01
Innate and adaptive immune responses both contribute to pathological CD4 T cell activation in HIV-1 infected Ugandans. PLoS One (2011) 0.98
Increased expression of interferon-gamma in hyperplastic lymph nodes from HIV-infected patients. Clin Exp Immunol (1993) 0.96
CD4+ lymphocytopenia due to common variable immunodeficiency mimicking AIDS. J Clin Pathol (1994) 0.92
Suppressed Th17 levels correlate with elevated PIAS3, SHP2, and SOCS3 expression in CD4 T cells during acute simian immunodeficiency virus infection. J Virol (2013) 0.89
Enhanced responsiveness to nuclear factor kappa B contributes to the unique phenotype of simian immunodeficiency virus variant SIVsmmPBj14. J Virol (1994) 0.89
Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages. World J Virol (2013) 0.88
HIV-1 and recombinant gp120 affect the survival and differentiation of human vessel wall-derived mesenchymal stem cells. Retrovirology (2011) 0.85
A Glucuronoxylomannan-Associated Immune Signature, Characterized by Monocyte Deactivation and an Increased Interleukin 10 Level, Is a Predictor of Death in Cryptococcal Meningitis. J Infect Dis (2016) 0.84
Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest (1993) 0.84
IL-27-induced gene expression is downregulated in HIV-infected subjects. PLoS One (2012) 0.82
Mucosal correlates of protection in HIV-1-exposed sero-negative persons. Am J Reprod Immunol (2014) 0.78
Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma. J Cancer Res Clin Oncol (2014) 0.78
Defective IL-6 secretion in HIV-infected haemophilia patients. Clin Exp Immunol (1993) 0.77
Cordelia, Goneril and the febrile response. Trans Am Clin Climatol Assoc (1997) 0.75
Divergent Annexin A1 expression in periphery and gut is associated with systemic immune activation and impaired gut immune response during SIV infection. Sci Rep (2016) 0.75
Early Secreted Antigenic Target of 6-kDa of Mycobacterium tuberculosis Stimulates IL-6 Production by Macrophages through Activation of STAT3. Sci Rep (2017) 0.75
Pathophysiology of CD4+ T-Cell Depletion in HIV-1 and HIV-2 Infections. Front Immunol (2017) 0.75
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med (1988) 9.21
Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med (1977) 8.24
Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science (1986) 7.81
Identification of breakpoints in intergenotypic recombinants of HIV type 1 by bootscanning. AIDS Res Hum Retroviruses (1995) 7.12
Effect of temperature on the vector efficiency of Aedes aegypti for dengue 2 virus. Am J Trop Med Hyg (1987) 5.53
Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg (1989) 4.79
Etiology of interepidemic periods of mosquito-borne disease. Proc Natl Acad Sci U S A (2000) 4.75
Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg (1988) 4.65
Structure of the cell wall anchor of surface proteins in Staphylococcus aureus. Science (1995) 4.27
A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. N Engl J Med (1991) 4.23
Who should own scientific papers? Science (1998) 3.62
Immunization against tularemia: analysis of the effectiveness of live Francisella tularensis vaccine in prevention of laboratory-acquired tularemia. J Infect Dis (1977) 3.51
Antibody capture immunoassay detection of japanese encephalitis virus immunoglobulin m and g antibodies in cerebrospinal fluid. J Clin Microbiol (1982) 3.44
Detection of diverse HIV-1 genetic subtypes in the USA. Lancet (1995) 3.41
Sequences of the malE gene and of its product, the maltose-binding protein of Escherichia coli K12. J Biol Chem (1984) 3.10
Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med (1995) 2.99
IL-10 inhibits human T cell proliferation and IL-2 production. J Immunol (1992) 2.94
Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr (1990) 2.84
Full-length sequence and mosaic structure of a human immunodeficiency virus type 1 isolate from Thailand. J Virol (1996) 2.83
Human immunodeficiency virus infections among civilian applicants for United States military service, October 1985 to March 1986. Demographic factors associated with seropositivity. N Engl J Med (1987) 2.81
HTLV-III in symptom-free seronegative persons. Lancet (1984) 2.71
Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood (1999) 2.65
Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med (1987) 2.59
Kinetics of IgM and IgG responses to Japanese encephalitis virus in human serum and cerebrospinal fluid. J Infect Dis (1985) 2.59
Genetic variants of HIV-1 in Thailand. AIDS Res Hum Retroviruses (1992) 2.52
Genetic diversity of the envelope glycoprotein from human immunodeficiency virus type 1 isolates of African origin. J Virol (1995) 2.48
The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med (1986) 2.44
Two antigenically distinct subtypes of human immunodeficiency virus type 1: viral genotype predicts neutralization serotype. J Infect Dis (1994) 2.42
Recovery of virtually full-length HIV-1 provirus of diverse subtypes from primary virus cultures using the polymerase chain reaction. Virology (1995) 2.38
Type-restricted neutralization of molecular clones of human immunodeficiency virus. Science (1988) 2.31
Use of gene fusions to determine a partial signal sequence of alkaline phosphatase. J Bacteriol (1979) 2.29
Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann Intern Med (1985) 2.25
Measurement of the false positive rate in a screening program for human immunodeficiency virus infections. N Engl J Med (1988) 2.22
Activation of suppressor T cells during Epstein-Barr-virus-induced infectious mononucleosis. N Engl J Med (1979) 2.21
Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol (1985) 2.20
Intracellular trehalose improves the survival of cryopreserved mammalian cells. Nat Biotechnol (2000) 2.20
The organization of the araBAD operon of Escherichia coli. Gene (1986) 2.16
Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science (1996) 2.11
Detection of Japanese encephalitis virus immunoglobulin M antibodies in serum by antibody capture radioimmunoassay. J Clin Microbiol (1982) 2.10
Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood (1996) 2.09
False-positive Western blot tests for antibodies to HTLV-III. JAMA (1986) 2.07
Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med (1981) 2.05
Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am J Trop Med Hyg (1985) 2.04
Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med (1986) 2.03
Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production by human B cells. J Exp Med (1983) 1.97
Human interleukin-10 can directly inhibit T-cell growth. Blood (1993) 1.93
NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med (1993) 1.92
Full-length sequence of an ethiopian human immunodeficiency virus type 1 (HIV-1) isolate of genetic subtype C. AIDS Res Hum Retroviruses (1996) 1.92
Genetic analysis of HIV-1 isolates from Brazil reveals presence of two distinct genetic subtypes. AIDS Res Hum Retroviruses (1994) 1.90
Direct measurement of human immunodeficiency virus seroconversions in a serially tested population of young adults in the United States Army, October 1985 to October 1987. Walter Reed Retrovirus Research Group. N Engl J Med (1989) 1.89
Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood (2001) 1.83
Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis). J Immunol (1985) 1.76
Frequent transmission of HTLV-III among spouses of patients with AIDS-related complex and AIDS. JAMA (1985) 1.76
Japanese encephalitis: immunocytochemical studies of viral antigen and inflammatory cells in fatal cases. Ann Neurol (1985) 1.73
HIV-1 genetic diversity. AIDS (1996) 1.69
Human immunodeficiency virus infections in teenagers. Seroprevalence among applicants for US military service. The Walter Reed Retrovirus Research Group. JAMA (1990) 1.67
Rubisco in marine symbiotic dinoflagellates: form II enzymes in eukaryotic oxygenic phototrophs encoded by a nuclear multigene family. Plant Cell (1996) 1.65
Heterosexually acquired HTLV-III/LAV disease (AIDS-related complex and AIDS). Epidemiologic evidence for female-to-male transmission. JAMA (1985) 1.65
Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest (1984) 1.63
Absence of true seroreversion of HIV-1 antibody in seroreactive individuals. JAMA (1993) 1.63
Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood (1997) 1.63
Evolution and probable transmission of intersubtype recombinant human immunodeficiency virus type 1 in a Zambian couple. J Virol (1997) 1.62
Primary isolation and serial passage of hepatitis A virus strains in primate cell cultures. J Clin Microbiol (1984) 1.61
Multicentric Castleman's disease in HIV infection. Int J STD AIDS (2006) 1.60
Chronic vaginal candidiasis in women with human immunodeficiency virus infection. JAMA (1987) 1.59
Molecular characterization of a neutralizing domain of the Japanese encephalitis virus structural glycoprotein. J Gen Virol (1989) 1.59
Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg (1989) 1.57
Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med (1998) 1.57
Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci U S A (1996) 1.52
B cell differentiation and immunoregulatory T cell function in human cord blood lymphocytes. J Clin Invest (1980) 1.51
Prevalence and incidence of HTLV-III infection in a prison. JAMA (1986) 1.48
Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns. J Virol (1991) 1.48
Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro. J Immunol (1979) 1.46
Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Res Hum Retroviruses (1996) 1.46
Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC-83) VEE virus vaccine. J Infect Dis (1977) 1.44
The current distribution of CD4+ T-lymphocyte counts among adults in the United States with human immunodeficiency virus infections: estimates based on the experience of the U.S. Army. U.S. Army Retrovirus Research Group. J Acquir Immune Defic Syndr (1990) 1.42
Naturally occurring genotypes of the human immunodeficiency virus type 1 long terminal repeat display a wide range of basal and Tat-induced transcriptional activities. J Virol (1994) 1.40
Constraints in T-B cooperation related to epitope topology on E. coli beta-galactosidase. I. The fine specificity of T cells dictates the fine specificity of antibodies directed to conformation-dependent determinants. Eur J Immunol (1985) 1.40
Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci U S A (2003) 1.38
Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. J Immunol (1995) 1.37
Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc Natl Acad Sci U S A (1991) 1.37
Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation. J Infect Dis (1988) 1.37
Epstein-Barr virus infection and immunoregulation in man. Adv Immunol (1985) 1.36
Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet (1985) 1.35
Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol (1994) 1.35
Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med (1986) 1.34